Skip to main content

Chesapeake Tumbles Toward Oblivion With Investors Losing Faith

Chesapeake Tumbles Toward Oblivion With Investors Losing Faith(Bloomberg) -- Chesapeake Energy Corp.’s options for dealing with its towering debt load are shriveling as the natural gas driller seeks to auction off shale fields it needs to stay afloat.Chesapeake’s bonds and shares plunged on Wednesday after Chief Executive Officer Doug Lawler mapped out a survival strategy predicated on a sweeping divestiture program that must be consummated within months in a market already glutted with North American gas holdings.The risky plan to raise as much as $500 million, coupled with an impending reverse-stock split aimed at avoiding delisting, spooked investors. The Oklahoma shale explorer’s bonds were among the worst junk-market performers for the day amid swelling doubt among holders that recent refinancing moves will be enough to manage its leveraged balance sheet.Once a vanguard of the U.S. shale revolution, Chesapeake has fallen headlong toward collapse as it and rival drillers flooded the U.S. with excess gas, crushing prices and destroying billions of dollars in value. Chesapeake, a brainchild of late shale pioneer Aubrey McClendon, lost more than 95% of its market value since Lawler was recruited to revive the company in 2013.“Our price target on this is zero,” said Sameer Panjwani, director of exploration and production research at Tudor, Pickering, Holt & Co. “Everyone is concerned with the debt load here. You either have to sell assets, which in this market is pretty tough to do, or you have to generate free cash flow, which they’re not doing well in this environment. They’re backed into a corner.”Up until now, Lawler’s campaign of belt tightening, job cuts and debt exchanges bought it time as he pursued plans to transform Chesapeake into an oil producer. But on Wednesday, the company’s second-lien bonds due in 2025 fell to about 66 cents on the dollar, well below their face value of 100 cents when sold in December.Default BetsCredit-derivatives traders are pricing in all-but-certain odds of a Chesapeake default in the next five years, with the cost to insure $10 million of debt in the credit-default swaps market surging to about $6.5 million upfront and $500,000 annually.The company has $209 million of bonds coming due in August, out of a total debt load of more than $9 billion.Chesapeake shares dipped 30% to 30.86 cents a share, the lowest close since McClendon and co-founder Tom Ward took the gas producer public in 1993.Fallow Fields“Significant portions” of the company’s portfolio aren’t being invested in as the company shrinks spending and focuses on its highest-return properties, Lawler told analysts and investors during a conference call.“As we think about the opportunities to meet the near-term maturities, we have a very large portfolio of things we are presently working on and will continue to look at for divestiture this year,” he said.What Bloomberg Intelligence SaysWhile crucial to aid liquidity, divestitures are curbing cash flow and set off a negative feedback loop of potentially lower output.\-- Vincent G. Piazza, analyst\--With assistance from David Wethe and Shannon D. Harrington.To contact the reporters on this story: Joe Carroll in Houston at jcarroll8@bloomberg.net;Allison McNeely in New York at amcneely@bloomberg.net;Sayer Devlin in New York at sdevlin13@bloomberg.netTo contact the editors responsible for this story: Simon Casey at scasey4@bloomberg.net, Joe Carroll, Carlos CaminadaFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.




from Yahoo Finance https://ift.tt/2TlJ8Fs

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be